Publication | Open Access

Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial

Breast OncologyMedicineClinical TrialsBreast CancerPharmacotherapyCancer TreatmentOncologyRadiation OncologyPhase 3Health Sciences